What are the cardiometabolic risks of polypharmacy with quetiapine and long-acting injectable paliperidone in patients with schizophrenia?
“Mr Ren” is a 32-year-old male with a history of chronic schizophrenia. The onset of his psychotic disorder was at aged 21 years. Previous trials of olanzapine and aripiprazole failed. He has been taking paliperidone palmitate 234 mg intramuscular monthly for the past 6 months but has experienced significant residual positive symptoms. He has a history of comorbid obesity and type 2 diabetes, but he does not have hyperlipidemia or hypertension.
At an outpatient visit, the psychiatrist discusses a trial of clozapine, which Mr Ren declines because of concerns about adverse effects of weight gain and his diabetes. Mr Ren reports significant initial insomnia and inquires about quetiapine, which he says helped him sleep during a previous psychiatric hospitalization. He asks about the cardiometabolic risks of polypharmacy with quetiapine and long-acting injectable paliperidone. As his psychiatrist, how would you respond?
Individuals with schizophrenia die 20 years prematurely on average compared with the general population,1 in part because of cardiometabolic disorders, including obesity, diabetes, hyperlipidemia, and hypertension.2 Cardiometabolic adverse effects are common with antipsychotic medications.3
Although it lacks a strong evidence base, antipsychotic polypharmacy (APP) is frequently used.4,5 Data on cardiometabolic effects of APP, which have the potential for increased adverse effects, are inconsistent and low quality.6
The Current Study
Eyles and colleagues7 used the UK Clinical Practice Research Datalink (CPRD) to investigate associations between APP exposure and risk of developing cardiometabolic disorders. Primary care data were obtained from more than 700 general practices in the United Kingdom. Data were linked to hospital episode statistics records and the Mental Health Services Data Set.
The authors conducted a cohort study using CPRD records for patients with ICD-10 or Read Codes for schizophrenia between July 1994 and August 2018. Cohort entry was date of first antipsychotic prescription within 6 months of an incident diagnosis of schizophrenia. Patients were followed for up to 5 years, with a median follow-up of 14 months. Patients were followed up to 5 years or until they had a prescription and/or a diagnostic code for diabetes, hypertension, hyperlipidemia, death, or lack of contact with the general practice.
Patients younger than18 years and those with a history of myocardial infarction or stroke were excluded. The authors formed 3 cohorts from the study population based on patients who did not have diabetes (cohort 1), hypertension (cohort 2), or hyperlipidemia (cohort 3).
The exposure of interest was time (days) exposed to antipsychotic polypharmacy vs monotherapy as well as whether APP was with first-generation and/or second-generation antipsychotics. The exposure periods were based on the duration of each prescription and included a 90-day washout period. Outcomes were time to incidence of diagnosis or prescription for diabetes, hypertension, or hyperlipidemia.
Covariates included age, sex, ethnicity, body mass index, Index of Multiple Deprivation score, smoking, alcohol and illicit drug use, practice region, year of diagnosis, number of comorbidities, number of consultations, hospitalizations, and mental health service encounters, and the ratio of the prescribed daily dose to defined daily dose. Data were analyzed using an even-time stratified multivariable Cox proportional hazards model with time-varying exposures on daily data and prescribed antipsychotic generation.
The study cohorts included 1633 (diabetes), 1268 (hypertension), and 1668 (hyperlipidemia) patients with schizophrenia. During follow-up, 4.4% developed diabetes, 6.6% developed hypertension, and 3.8% developed hyperlipidemia. In this study, patients diagnosed with cardiometabolic comorbidities were significantly older and had more medical comorbidities. In the adjusted Cox models, compared with antipsychotic monotherapy, there was no evidence that APP was associated with an increased risk of diabetes or hyperlipidemia.
However, APP was associated with an increased risk of hypertension (HR, 3.2; 95% CI, 1.2-8.4). The risk was higher in patients with APP exclusively with first-generation agents compared with combined first- and second-generation agents. There was no evidence that exclusive second-generation APP was associated with an increased risk of cardiometabolic disorders compared with APP with first-generation agents.
Compared with monotherapy, APP had an increased risk of hypertension, and risks should be considered when making clinical decisions. Study strengths include use of a prospective, representative, population-based database of primary care in the United Kingdom, which reduced selection bias. Another strength is that the CPRD includes detailed medical information, and the authors considered multiple potential confounding factors.
A limitation of the present study is that patients with unstable schizophrenia are managed in secondary/tertiary care, and prescription data for these patients were not available. Furthermore, there were small numbers of participants with APP with only second-generation agents, which may have influenced findings for diabetes and hyperlipidemia. The observational nature of the study also delimits making causal inferences regarding these associations.
The Bottom Line
Antipsychotic polypharmacy (vs monotherapy) is associated with an increased risk of hypertension, but not diabetes or hyperlipidemia. Regular blood pressure monitoring, and antihypertensive treatment when indicated, appear warranted.
Dr Miller is a professor in the Department of Psychiatry and Health Behavior at Augusta University in Georgia. He is on the Editorial Board and serves as the schizophrenia section chief for Psychiatric Times®. The author reports that he receives research support from Augusta University, the National Institute of Mental Health, and the Stanley Medical Research Institute.
1. Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014;10:425-448.
2. Bushe C, Holt R. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry Suppl. 2004;47:S67-S71.
3. Rojo LE, Gaspar PA, Silva H, et al. Metabolic syndrome and obesity among users of second generation antipsychotics: a global challenge for modern psychopharmacology. Pharmacol Res. 2015;101:74-85.
4. Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35(2):443-457.
5. Harrington M, Lelliott P, Paton C, et al. The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. Psychiatric Bull. 2002;26(11):414-418.
6. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10):1079-1087.
7. Eyles E, Margelyte R, Edwards HB, et al. Antipsychotic medication and risk of metabolic disorders in people with schizophrenia: a longitudinal study using the UK Clinical Practice Research Datalink. Schizophr Bull. 2023;sbad126.